Vertex announces Irish approval for funding of Kalydeco Vertex Pharmaceuticals announced that the Health Service Executive in the Republic of Ireland will fund Kalydeco, the first medicine to treat the underlying cause of cystic fibrosis, for people ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Vertex shares should be owned ahead of data, says JMP Securities JMP Securities expects Phase 3 data for Kalydeco in combination with corrector lumacaftor, expected to be announced mid-year, to be positive. It recommends that ivnestors own the stock ahead of the data. The firm notes that Vertex received a label expansion for Kalydeco fro mthe FDA, and it reiterates a $115 price target and Outperform rating on the stock.